What eGFR threshold is required to initiate dapagliflozin, and what dosing regimen should be used at various eGFR levels?

Dapagliflozin Initiation Based on eGFR

Initiate dapagliflozin at 10 mg once daily in adults with eGFR ≥25 mL/min/1.73 m² for kidney and cardiovascular protection, and continue it even if eGFR subsequently falls below this threshold unless dialysis is initiated. 1, 2

eGFR Thresholds for Initiation

The guidance differs based on your treatment indication:

For Kidney Protection, Heart Failure, or Cardiovascular Risk Reduction

• Initiate at eGFR ≥25 mL/min/1.73 m² using 10 mg once daily 1, 3
• The 2024 KDIGO guidelines now recommend SGLT2i initiation at eGFR ≥20 mL/min/1.73 m² for adults with CKD and either:
  • Urine ACR ≥200 mg/g, OR
  • Heart failure (regardless of albuminuria level) 2
• For patients with eGFR 20-45 mL/min/1.73 m² and ACR <200 mg/g, initiation is still reasonable but with slightly weaker evidence (2B recommendation) 2

For Glycemic Control in Type 2 Diabetes

• Do NOT initiate if eGFR <45 mL/min/1.73 m² for glucose-lowering purposes 1, 3
• The drug becomes ineffective for glycemic control below this threshold due to its mechanism of action
• If already on dapagliflozin for glycemic control and eGFR falls below 45, continue the medication for its kidney and cardiovascular benefits 3

Dosing Regimen

Single dose across all eGFR levels:

• 10 mg once daily for all non-glycemic indications (kidney protection, heart failure, CV risk reduction) 1, 3
• 5 mg once daily can be used as starting dose for glycemic control in diabetes, with option to increase to 10 mg 1

Critical point: Unlike many other medications, dapagliflozin does not require dose adjustment based on eGFR level. The same 10 mg dose is used whether eGFR is 60,40, or 25 mL/min/1.73 m² 3, 1.

Continuation Below Initiation Threshold

Once started, continue dapagliflozin even if eGFR falls below initiation thresholds 2, 3, 1:

• If eGFR drops below 25 mL/min/1.73 m² after initiation, continue 10 mg daily
• If eGFR drops below 20 mL/min/1.73 m² after initiation, continue 10 mg daily
• Only discontinue if dialysis is initiated or the drug is not tolerated 2, 1

This approach is supported by trial protocols (CREDENCE, DAPA-CKD) that specified continuation when eGFR fell below initiation thresholds, demonstrating preserved kidney and cardiovascular benefits 3, 4.

The eGFR "Dip" Phenomenon

Expect and accept an initial eGFR decline of 2-3 mL/min/1.73 m² within the first 2 weeks 5, 4:

• This acute dip is hemodynamic and reversible, not nephrotoxic
• It reflects reduced intraglomerular pressure (a protective mechanism)
• Do not discontinue based on this expected decline 2, 3
• The chronic eGFR slope after week 2 shows significant benefit, with dapagliflozin slowing decline by approximately 1-2 mL/min/1.73 m²/year compared to placebo 5, 4

Monitoring Requirements

Standard CKD monitoring frequency is sufficient 2:

• SGLT2i initiation does not necessitate more frequent monitoring
• Check eGFR at baseline before initiation 1
• Continue routine monitoring per your usual CKD protocol
• The reversible eGFR decrease is generally not an indication to discontinue 2

Clinical Context Matters

The most recent evidence supports broader initiation criteria:

Strongest evidence for initiation at eGFR 20-25 mL/min/1.73 m² exists for patients with:

• Albuminuria (ACR ≥200 mg/g) 2, 4
• Heart failure 2, 3
• Type 2 diabetes with CKD 2, 3

The landmark DAPA-CKD trial enrolled patients with eGFR 25-75 mL/min/1.73 m² and demonstrated a 39% risk reduction in the composite of ≥50% sustained eGFR decline, ESKD, or CV/renal death (HR 0.61,95% CI 0.51-0.72, p<0.0001) 4. Importantly, 15% of participants had baseline eGFR <30 mL/min/1.73 m², and benefits were consistent across all eGFR subgroups 4.

Safety Considerations

Withhold temporarily during:

• Prolonged fasting or major surgery (hold ≥3 days before if possible) 2, 1
• Critical medical illness when ketosis risk is elevated 2, 1
• Resume when clinically stable and oral intake restored 1

Volume status:

• Assess and correct volume depletion before initiation 1
• Consider proactive diuretic dose reduction in high-risk patients 3
• Absolute risk of hypovolemia remains low, especially at lower eGFR 3

The evidence consistently demonstrates that glucose-lowering efficacy diminishes as eGFR declines, but kidney and cardiovascular benefits are preserved across the entire eGFR range studied 3, 4.